Shield Therapeutics plc (AIM:STX)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
ACCRUFeR®/FeRACCRU®	49.70M	32.18M	13.09M	5.50M	2.06M
ACCRUFeR®/FeRACCRU® Growth	54.45%	145.93%	137.95%	167.35%	-85.50%
Total	49.70M	32.18M	13.09M	5.50M	2.06M
Total Growth	54.45%	145.93%	137.95%	167.35%	-85.50%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
The Netherlands	2.76M	2.14M	1.50M	1.78M	1.23M
The Netherlands Growth	28.66%	43.28%	-15.77%	44.37%	-
Canada	831.00K	320.00K	-	185.00K	-
Canada Growth	159.69%	-	-	-	-
South Korea	-	122.00K	20.00K	6.00K	744.73K
South Korea Growth	-	510.00%	233.33%	-99.19%	-
Japan	338.00K	322.00K	-	-	-
Japan Growth	4.97%	-	-	-	-
United States	45.78M	29.27M	11.57M	3.53M	82.60K
United States Growth	56.37%	153.02%	228.13%	4168.87%	-
Total	49.70M	32.18M	13.09M	5.49M	2.06M
Total Growth	54.45%	145.93%	138.26%	167.01%	-85.50%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 19, 2026

Data Sources Report a data error